MA49339A - Conjugués insuline-fc à extension oligomère - Google Patents
Conjugués insuline-fc à extension oligomèreInfo
- Publication number
- MA49339A MA49339A MA049339A MA49339A MA49339A MA 49339 A MA49339 A MA 49339A MA 049339 A MA049339 A MA 049339A MA 49339 A MA49339 A MA 49339A MA 49339 A MA49339 A MA 49339A
- Authority
- MA
- Morocco
- Prior art keywords
- conjugates
- oligomer extended
- extended insulin
- relates
- oligomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne le domaine des conjugués protéiques. Plus particulièrement, l'invention concerne des insulines à extension oligomère, avec des polypeptides monomères fc liés de manière covalente, destinées à être utilisées dans le traitement d'un trouble ou d'un état métabolique, et des procédés de production de tels conjugués d'insuline-fc à extension oligomère. L'invention concerne également de nouveaux fragments fc, des produits intermédiaires et l'utilisation de tels produits intermédiaires dans des processus de synthèse des conjugués d'insuline-fc à extension oligomère selon l'invention. L'invention concerne enfin des compositions pharmaceutiques comprenant les conjugués d'insuline-fc à extension oligomère selon l'invention, et l'utilisation de telles compositions pour le traitement ou la prévention d'états pathologiques associés à des troubles ou à des états métaboliques.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17164950 | 2017-04-05 | ||
EP17208780 | 2017-12-20 | ||
EP18151228 | 2018-01-11 | ||
CN201810276163 | 2018-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49339A true MA49339A (fr) | 2020-02-12 |
Family
ID=61868527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049339A MA49339A (fr) | 2017-04-05 | 2018-04-04 | Conjugués insuline-fc à extension oligomère |
Country Status (6)
Country | Link |
---|---|
US (1) | US11471537B2 (fr) |
EP (1) | EP3606560A2 (fr) |
JP (1) | JP2020513019A (fr) |
CN (1) | CN110505885A (fr) |
MA (1) | MA49339A (fr) |
WO (1) | WO2018185131A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016193380A1 (fr) | 2015-06-02 | 2016-12-08 | Novo Nordisk A/S | Insulines à extensions recombinées polaires |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
MA49339A (fr) | 2017-04-05 | 2020-02-12 | Novo Nordisk As | Conjugués insuline-fc à extension oligomère |
WO2019074110A1 (fr) * | 2017-10-13 | 2019-04-18 | 株式会社ボナック | Molécule d'acide nucléique simple brin et son procédé de production |
JP2022502467A (ja) * | 2018-10-10 | 2022-01-11 | ノヴォ ノルディスク アー/エス | オリゴマー伸長インスリン−fcコンジュゲートおよびそれらの医学的使用 |
JP2022512057A (ja) * | 2018-12-17 | 2022-02-02 | 栄昌生物制薬(烟台)股▲分▼有限公司 | 抗体薬物複合体のためのリンカーおよびその使用 |
CN111217915B (zh) * | 2019-01-08 | 2021-05-14 | 东莞太力生物工程有限公司 | GLP-1类似物Fc融合多肽及其应用 |
WO2023064711A2 (fr) * | 2021-10-14 | 2023-04-20 | Akston Biosciences Corporation | Protéines de fusion insuline-fc à action ultra-longue et méthodes d'utilisation |
TW202339790A (zh) | 2021-11-15 | 2023-10-16 | 美商美國禮來大藥廠 | 可保存之調配物 |
WO2023247640A1 (fr) * | 2022-06-23 | 2023-12-28 | Sanofi | Insulines à chaîne unique et leurs conjugués fc |
CN115850385B (zh) * | 2022-07-04 | 2023-08-11 | 北京惠之衡生物科技有限公司 | 一种促表达肽及其应用 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE257197C (fr) | ||||
DE286509C (fr) | ||||
US3914252A (en) | 1971-03-15 | 1975-10-21 | Continental Oil Co | Preparation of N-iodocompounds |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
DE69635026T2 (de) | 1995-09-21 | 2006-05-24 | Genentech Inc., San Francisco | Varianten des menschlichen wachstumshormons |
WO1997034631A1 (fr) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Domaines analogues a l'immunoglobuline a demi-vies prolongees |
WO1998022577A1 (fr) | 1996-11-15 | 1998-05-28 | Maria Grazia Masucci | Proteines de fusion a demi-vie allongee |
IL133974A0 (en) | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
JP4944324B2 (ja) | 1999-07-13 | 2012-05-30 | ボルダー バイオテクノロジー, インコーポレイテッド | 免疫グロブリン融合タンパク質 |
EP1240337B1 (fr) | 1999-12-24 | 2006-08-23 | Genentech, Inc. | Methodes et compositions permettant de prolonger les demi-vies d'elimination de composes bioactifs |
US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20060183197A1 (en) | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
JP2004524020A (ja) | 2001-01-11 | 2004-08-12 | マキシゲン・エイピーエス | 改良された成長ホルモン分子 |
US20020169125A1 (en) | 2001-03-21 | 2002-11-14 | Cell Therapeutics, Inc. | Recombinant production of polyanionic polymers and uses thereof |
WO2003042245A2 (fr) | 2001-11-12 | 2003-05-22 | University Of Wales College Of Medicine | Variations de l'hormone de croissance chez les humains et leurs utilisations |
GB2389115B (en) | 2001-12-14 | 2005-03-16 | Asterion Ltd | Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone |
EP1553975B8 (fr) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Variants fc optimises et methodes destinees a leur generation |
US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
AU2004282984B2 (en) | 2003-11-13 | 2011-07-14 | Hanmi Science Co., Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
KR100594607B1 (ko) | 2004-11-03 | 2006-06-30 | 재단법인서울대학교산학협력재단 | 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법 |
US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
NZ556726A (en) | 2005-01-25 | 2011-04-29 | Cell Therapeutics Inc | Conjugates of biologically active proteins having a modified in vivo half-life |
US20090036353A1 (en) | 2005-01-27 | 2009-02-05 | Novo Nordisk A/S | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers |
JP2008530178A (ja) | 2005-02-16 | 2008-08-07 | ノボ ノルディスク アクティーゼルスカブ | 構造的に明確に定義された分枝重合体と抱合されたインスリン分泌性薬剤の誘導体 |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
AU2006324488B2 (en) | 2005-12-12 | 2013-03-21 | Abcam Limited | Production of conjugates |
EP1971355B1 (fr) | 2005-12-20 | 2020-03-11 | Duke University | Procedes et compositions pour l'administration d'agents actifs a proprietes pharmacologiques ameliorees |
AU2007223888A1 (en) | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Genetic packages and uses thereof |
JP5256199B2 (ja) | 2006-08-07 | 2013-08-07 | テヴァ バイオファーマシューティカルズ ユーエスエー,インコーポレーティッド | アルブミン−インスリン融合タンパク質 |
PT2074141T (pt) | 2006-09-22 | 2016-11-10 | Novo Nordisk As | Análogos de insulina resistentes a proteases |
ES2410886T3 (es) | 2006-10-26 | 2013-07-03 | Janssen Biotech, Inc. | Métodos para la adaptación al ser humano de anticuerpos monoclonales |
WO2008049711A1 (fr) | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Insuline à peptide ajouté |
US20100303723A1 (en) | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
WO2008092117A2 (fr) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Nouvelles insertions, délétions et substitutions d'immunoglobulines |
KR20080095141A (ko) | 2007-04-23 | 2008-10-28 | 포항공과대학교 산학협력단 | 인간 알부민 링커를 통하여 면역글로불린의 Fc에 결합된생리학적 활성 폴리펩티드의 융합 폴리펩티드, 및 이의제조방법 |
JP5577243B2 (ja) | 2007-05-30 | 2014-08-20 | ポステク アカデミー−インダストリー ファウンデイション | 免疫グロブリン融合タンパク質 |
US20100267934A1 (en) | 2007-05-31 | 2010-10-21 | Genmab A/S | Stable igg4 antibodies |
WO2009015345A1 (fr) | 2007-07-25 | 2009-01-29 | Amgen Inc. | Compositions pharmaceutiques comprenant des protéines de fusion fc |
KR20100058541A (ko) | 2007-08-15 | 2010-06-03 | 아뮤닉스 인코포레이티드 | 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법 |
WO2009053368A1 (fr) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Ifn-bêta unique fusionné à un fragment fc d'igg muté |
RU2532226C2 (ru) | 2008-06-20 | 2014-10-27 | Новартис Аг | Иммуноглобулины с уменьшенной агрегацией |
WO2010001196A1 (fr) | 2008-07-02 | 2010-01-07 | Koninklijke Philips Electronics N.V. | Configuration de ressort en v et ensembles de fixation d'extrémité pour celle-ci destinés à être utilisés dans un appareil de soins d'hygiène corporelle |
MY151184A (en) | 2008-07-23 | 2014-04-30 | Hanmi Science Co Ltd | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
ES2730800T3 (es) | 2009-02-03 | 2019-11-12 | Amunix Pharmaceuticals Inc | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
US9493578B2 (en) * | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
CA2774552A1 (fr) | 2009-09-30 | 2011-04-07 | Glaxo Group Limited | Fusions de medicaments et conjugues presentant une demi-vie prolongee |
AU2010318542B2 (en) * | 2009-10-29 | 2015-08-27 | Janssen Biotech Inc. | Antibody glycosylation variants |
US8637637B2 (en) | 2010-01-12 | 2014-01-28 | Bill Nai-Chau Sun | Fc fusion proteins of human growth hormone |
AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
EP2571510B1 (fr) | 2010-05-21 | 2018-08-08 | XL-protein GmbH | Polypeptides de bobine aléatoires en proline/alanine biosynthétique |
KR101337797B1 (ko) | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
WO2012138920A1 (fr) | 2011-04-05 | 2012-10-11 | Martin-Protean, Llc | Isolement de peptides contenant de la cystéine |
UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
KR102057356B1 (ko) | 2012-02-27 | 2019-12-18 | 아뮤닉스 파마슈티컬스, 인크. | Xten 콘주게이트 조성물 및 그의 제조 방법 |
WO2013170272A2 (fr) | 2012-05-11 | 2013-11-14 | Alexander Krantz | Marquage spécifique d'un site et administration ciblée de protéines pour le traitement d'un cancer |
US20160115216A1 (en) | 2013-06-07 | 2016-04-28 | Novo Nordisk A/S | Method for Making Mature Insulin Polypeptides |
US10286078B2 (en) | 2013-09-13 | 2019-05-14 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
WO2015081073A2 (fr) | 2013-11-26 | 2015-06-04 | The Brigham And Women's Hospital, Inc. | Compositions et procédés pour moduler une réponse immunitaire |
AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
SG11201606597QA (en) | 2014-03-05 | 2016-09-29 | Ucb Biopharma Sprl | Multimeric fc proteins |
ES2905085T3 (es) | 2014-09-17 | 2022-04-07 | Novo Nordisk As | Anticuerpos que pueden unirse a dos epítopos en el inhibidor de la vía del factor tisular (1-161) |
CN107810202A (zh) | 2015-02-17 | 2018-03-16 | 韩美药品株式会社 | 长效胰岛素或胰岛素类似物复合物 |
AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
WO2016193380A1 (fr) | 2015-06-02 | 2016-12-08 | Novo Nordisk A/S | Insulines à extensions recombinées polaires |
CA2994853C (fr) * | 2015-08-14 | 2023-06-27 | Rc Biotechnologies, Inc. | Lieurs covalents dans des conjugues anticorps-medicament et leurs procedes de production et d'utilisation |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
MA49339A (fr) | 2017-04-05 | 2020-02-12 | Novo Nordisk As | Conjugués insuline-fc à extension oligomère |
-
2018
- 2018-04-04 MA MA049339A patent/MA49339A/fr unknown
- 2018-04-04 US US16/500,897 patent/US11471537B2/en active Active
- 2018-04-04 WO PCT/EP2018/058550 patent/WO2018185131A2/fr unknown
- 2018-04-04 EP EP18715032.1A patent/EP3606560A2/fr not_active Withdrawn
- 2018-04-04 JP JP2019554912A patent/JP2020513019A/ja not_active Withdrawn
- 2018-04-04 CN CN201880023755.XA patent/CN110505885A/zh not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN110505885A (zh) | 2019-11-26 |
WO2018185131A2 (fr) | 2018-10-11 |
WO2018185131A3 (fr) | 2018-11-15 |
US20200261595A1 (en) | 2020-08-20 |
US11471537B2 (en) | 2022-10-18 |
EP3606560A2 (fr) | 2020-02-12 |
JP2020513019A (ja) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49339A (fr) | Conjugués insuline-fc à extension oligomère | |
MX2019012081A (es) | Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso. | |
PH12018502429A1 (en) | Antibody molecules for cancer treatment | |
MX2018005387A (es) | Variantes de fgf21. | |
AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
MX2017014083A (es) | Polipeptido de fusion anti-cancer. | |
MX2018001567A (es) | Novedosos polipeptidos de fusion especificos para lag-3 y pd-1. | |
WO2016187220A3 (fr) | Anticorps anti-ror1 | |
WO2017077329A3 (fr) | Acides nucléiques, peptides et méthodes | |
MX2017014716A (es) | Polipeptido de fusion anti-cancer. | |
MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
WO2015128403A3 (fr) | Nouveaux dérivés de l'insuline et leurs utilisations médicales | |
MX2020006999A (es) | Farmaceuticos de peptidos mejorados para el tratamiento de nash y otros trastornos. | |
MX2017000378A (es) | ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS. | |
MX2018002223A (es) | Derivados de insulina novedosos y usos medicos de los mismos. | |
MX2019004280A (es) | Organonitro-sulfoalquilo y compuestos relacionados y composiciones farmacéuticas para uso en medicina. | |
WO2018154118A3 (fr) | Nouveaux composés aromatiques | |
MX2023010328A (es) | Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso. | |
PH12021550872A1 (en) | Therapeutic compounds | |
MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
MX2021001545A (es) | Péptidos penetrantes celulares. | |
MX2018009499A (es) | Anticuerpos monoclonales especificos de egfl6 y metodos de su uso. | |
ZA202201827B (en) | Therapeutic fusion proteins | |
MX2019014365A (es) | Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos. | |
WO2020039088A3 (fr) | Nouveaux composés |